NCT07181733

Brief Summary

MetS is a syndrome characterized by a combination of diabetes, hypertension and visceral obesity, altered blood lipids, beginning in childhood, leading to chronic disease in adulthood. Adult criteria for defining MetS require a minimum of 3 risk factors, listed in the NCEP ATP III (National Cholesterol Education Program, Adult Treatment Panel III, ATP III), they are hyperglycaemia, hypertriglyceridemia, low HDL-C, hypertension, obesity and increased waist circumference. The pediatric definitions are described mainly by Cooks, Zimmet and de Ferranti are as well based on the presence of ≥ 3 symptoms: obesity (BMI) , waist circumference, glucose intolerance, dyslipidaemia (high triglycerides and/or low HDL-C), High BP. Pediatric criteria of MetS are not univocally defined and symptoms may be fluctuant in adolescent period, therefore the prevalence ranges from 4.2%13 to 9.2%. A number of researchers have used factor analysis of MetS components to develop a risk score to identify children at higher risk for developing MetS. Several MetS risk factors have origins during the prenatal and early postnatal period. In particular, it is known that preterm newborns are more prone to develop this condition once adults, but little is known about the adolescent transition, particularly, in Italy. From 2008 - 2011, thirty-four full-term and 36 premature infants were studied, evaluating echocardiographic parameters and BNP concentrations during the first month of life. In this population, now adolescents, it was decided to measure BNP, both current and previous values, in order to verify whether this parameter can be associated with MetS and meet the need to identify high-risk children. Adolescents affected by MetS were defined on the basis of the available literature: they must present ≥ 3 of the following signs: hyperglycaemia, dyslipidaemia (triglycerides and HDL-C), arterial hypertension, obesity (BMI and waist circumference). Other blood parameters were also evaluated as associated factors, such as white blood cell count, glycosylated haemoglobin, creatinine, urea nitrogen, and suPAR. Doppler echocardiography and tissue Doppler parameters, psychosocial variables (KIDSCREEN-10). BNP has been shown to play a role not only in heart disease but also in adult patients with obesity, insulin resistance, and diabetes, all of which are present in MetS. Therefore, the primary objective is to assess whether BNP can be an index associated with adolescent MetS. The opportunity was taken to evaluate a population of premature and full-term adolescents. BNP was previously studied in the first month of life, and it is possible to establish a correlation with the adolescent situation. Therefore, the cohort of newborns who are now between 13 and 15 years of age will be recalled. The data available in the literature and clinical experience suggest a prevalence of metabolic syndrome of between approximately 5 and 10%.

Trial Health

57
Monitor

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Trial has exceeded expected completion date
Enrollment
70

participants targeted

Target at P25-P50 for all trials

Timeline
Completed

Started May 2024

Geographic Reach
1 country

1 active site

Status
recruiting

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

May 8, 2024

Completed
10 months until next milestone

First Submitted

Initial submission to the registry

March 3, 2025

Completed
7 months until next milestone

First Posted

Study publicly available on registry

September 18, 2025

Completed
3 months until next milestone

Primary Completion

Last participant's last visit for primary outcome

December 31, 2025

Completed
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

December 31, 2025

Completed
Last Updated

September 18, 2025

Status Verified

March 1, 2025

Enrollment Period

1.6 years

First QC Date

March 3, 2025

Last Update Submit

September 12, 2025

Conditions

Keywords

adolescentBNP

Outcome Measures

Primary Outcomes (1)

  • Association of BNP with MetS in adolescent period

    we define MetS when an adolescent presents 3 of the following symptoms: hyperglycemia (\>110 mg/dl), dyslipidemia (triglycerides \<= 120 mg/dl and/or HDL-C \< 60 mg/dl), High BP (systolic \>120 mmHg diastolic \>80 mmHg) , obesity (BMI \> 30 and waist circumference \> 0.5).

    December 2025

Secondary Outcomes (3)

  • association of BNP in neonatal period and adolescents biomedical measurements

    December 2025

  • Association of adolescent BNP and MetS within categories of psychosocial variables (as identified by the KIDSCREEN-10 instrument) which are established to have a role in the development of MetS

    December 2025

  • Association of BNP in neonatal period with MetS

    December 2025

Study Arms (2)

subjects adolescents, born preterm/IUGR

subjects adolescents, born at term

Eligibility Criteria

Age13 Years - 18 Years
Sexall
Healthy VolunteersNo
Age GroupsChild (0-17), Adult (18-64)
Sampling MethodNon-Probability Sample
Study Population

patients whose BNP concentration and echocardiographic parameters was analysed during their first month of life (2009-11) of life at Fondazione IRCCS Policlinico San Matteo

You may qualify if:

  • adolescents whose BNP concentration and echocardiographic parameters analysed during their first month of life (2009-11)

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

U.O.S. Cardiologia Pediatrica

Pavia, pavia, 27100, Italy

RECRUITING

MeSH Terms

Conditions

Metabolic Syndrome

Condition Hierarchy (Ancestors)

Insulin ResistanceHyperinsulinismGlucose Metabolism DisordersMetabolic DiseasesNutritional and Metabolic Diseases

Central Study Contacts

Alessia C.A. Codazzi, MD

CONTACT

Study Design

Study Type
observational
Observational Model
CASE CONTROL
Time Perspective
CROSS SECTIONAL
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
Principal Investigator

Study Record Dates

First Submitted

March 3, 2025

First Posted

September 18, 2025

Study Start

May 8, 2024

Primary Completion

December 31, 2025

Study Completion

December 31, 2025

Last Updated

September 18, 2025

Record last verified: 2025-03

Data Sharing

IPD Sharing
Will not share

Locations